<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute otitis media in children: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute otitis media in children: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute otitis media in children: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen I Pelton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paula Tähtinen, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn C Isaacson, MD, FAAP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute otitis media (AOM), also called purulent otitis media and suppurative otitis media, is a common problem in children and accounts for a large proportion of pediatric antibiotic use.</p><p>The treatment of uncomplicated AOM will be reviewed here. The epidemiology, pathogenesis, diagnosis, complications, and prevention of AOM are discussed separately, as is otitis media with effusion (serous otitis media).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5966.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management"</a>.)</p><p></p><p class="headingAnchor" id="H397119285"><span class="h1">DIAGNOSIS OF AOM</span><span class="headingEndMark"> — </span>The clinical diagnosis of AOM requires one or more of the following [<a href="#rid1">1,2</a>] (see  <a class="medical medical_review" href="/z/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Bulging of the tympanic membrane  (<a class="graphic graphic_picture graphicRef63268" href="/z/d/graphic/63268.html" rel="external">picture 1</a>) – Children with severe/marked bulging of the tympanic membrane appear to benefit most from antibiotic therapy [<a href="#rid3">3</a>]. Bulging of the tympanic membrane is more likely to be associated with a bacterial pathogen in the middle ear [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of acute inflammation (eg, marked erythema of the tympanic membrane and fever or ear pain) <strong>and</strong> middle ear effusion – Although signs of acute inflammation and middle ear effusion without bulging may represent early AOM, it is challenging for young children to localize pain to the ear [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perforation of the tympanic membrane with acute purulent otorrhea if acute otitis externa has been excluded. (See  <a class="medical medical_review" href="/z/d/html/6866.html" rel="external">"External otitis: Pathogenesis, clinical features, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p>Accurate diagnosis ensures appropriate treatment for children with AOM, who require antibiotic therapy, and avoidance of antibiotics in children with otitis media with effusion, in whom antibiotics are unnecessary.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL COURSE WITHOUT ANTIBIOTICS</span><span class="headingEndMark"> — </span>The acute symptoms and signs of AOM often resolve within three days whether or not children are treated with antibiotics [<a href="#rid6">6-8</a>]. Antibiotic administration has been demonstrated to slightly hasten the resolution of pain. In a meta-analysis of seven randomized trials comparing antibiotics with placebo in 2320 children with AOM, 16 percent of those who did not receive antibiotics continued to have pain at two to three days (as compared with 11 percent of children who received antibiotic therapy) [<a href="#rid9">9</a>]. In a separate meta-analysis of randomized and observational studies in 1409 children who did not receive antibiotics, ear pain resolved within three days in 50 percent and within seven to eight days in 90 percent [<a href="#rid8">8</a>]. (See <a class="local">'Antibiotic therapy versus observation'</a> below.)</p><p>Middle ear effusion associated with AOM usually resolves spontaneously within several weeks, often by four to six weeks  (<a class="graphic graphic_figure graphicRef81406" href="/z/d/graphic/81406.html" rel="external">figure 1</a>) [<a href="#rid10">10-13</a>]. The clinical features, complications, and management of persistent middle ear effusion are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5966.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">MANAGEMENT OF PAIN</span><span class="headingEndMark"> — </span>Pain management is a mainstay of the treatment of AOM in children [<a href="#rid1">1,14</a>]. We provide treatment to reduce ear pain in children whether or not they are treated with antibiotics. Pain is a common feature of AOM and may be severe [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral and topical analgesics </strong>– We suggest oral <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> or <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> rather than other interventions for treatment of ear pain in children with AOM. With severe pain unresponsive to either ibuprofen or acetaminophen alone, a combination of both ibuprofen and acetaminophen may be needed.</p><p></p><p class="bulletIndent1">Although topical anesthetics applied to the tympanic membrane appear to be effective in relieving ear pain [<a href="#rid15">15,16</a>], they are not licensed for this indication in the United States. In addition, the US Food and Drug Administration added a boxed warning to viscous lidocaine after severe adverse events were reported in infants and children (primarily when it was used for teething or stomatitis). Topical procaine or lidocaine preparations should be used with caution in children and avoided in those with tympanic membrane perforation. Topical benzocaine is avoided in children &lt;2 years because of the risk of methemoglobinemia [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Topical anesthetics'</a>.)</p><p></p><p class="bulletIndent1">Limited evidence from randomized trials suggests that <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>, <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a>, and topical analgesics are effective in reducing ear pain compared with placebo or no treatment [<a href="#rid18">18,19</a>]. In a systematic review of randomized trials of nonsteroidal anti-inflammatory drugs and acetaminophen for pain relief in AOM that included 219 children, fewer children in the ibuprofen (7 percent) or acetaminophen (10 percent) groups than in the placebo group (25 percent) had pain at 48 hours, with no difference in the rate of adverse effects; all of the children received antibiotics [<a href="#rid18">18</a>]. Ibuprofen and acetaminophen appeared to be equally effective, although data were limited.</p><p></p><p class="bulletIndent1">We suggest not applying heat or cold to the external ear or instillation of olive oil or herbal extracts into the external auditory canal to treat pain in children with AOM. The effectiveness of these therapies is unproven and they may be harmful [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic tympanocentesis</strong> – Therapeutic tympanocentesis or myringotomy may be helpful in children with severe pain unresponsive to both analgesia and antibiotic treatment [<a href="#rid20">20</a>]. Therapeutic tympanocentesis or myringotomy are rarely needed but may be necessary with AOM caused by multidrug resistant otopathogens. It also may have other benefits. In a longitudinal prospective study, tympanocentesis with complete evacuation of middle ear fluid in combination with antimicrobial therapy was associated with decreased risk of treatment failure, becoming otitis prone, and tympanostomy tube placement [<a href="#rid21">21,22</a>]. Even if middle ear pus is not evacuated, tympanocentesis creates a pathway that may permit drainage (otorrhea), which reduces pressure and pain in the middle ear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of ear pain during airplane descent</strong> – Children with eustachian tube dysfunction, including those with AOM, may have ear pain during airplane travel, particularly during airplane descent [<a href="#rid23">23,24</a>]. With airplane descent, the pressure in the cabin increases to that at landing altitude. If middle ear pressure does not increase accordingly (ie, if the eustachian tube "locks in" the reduced pressure due to obstruction of the nasopharyngeal orifice), the tympanic membrane may be forced medially and stretched, which can lead to painful barotrauma: bleeding into the tympanic membrane  (<a class="graphic graphic_picture graphicRef93461" href="/z/d/graphic/93461.html" rel="external">picture 2</a>), formation of fluid exudates in the middle ear, and occasionally tympanic membrane rupture [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/6845.html" rel="external">"Ear barotrauma", section on 'Etiologies'</a>.)</p><p></p><p class="bulletIndent1">Although interventions to equalize middle ear and atmospheric pressure have not been well studied in controlled trials, the following interventions may help to open the eustachian tube to equalize middle ear pressure during descent [<a href="#rid26">26</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants and young children – Sucking on a pacifier or bottle; suctioning the nose with a nasal bulb</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For older children – Chewing on gum or food; autoinflation via the Valsalva maneuver (forced exhalation with the mouth and nose closed) or a purpose-manufactured nasal balloon [<a href="#rid27">27</a>]</p><p></p><p class="bulletIndent1">We suggest avoiding preflight treatment with antihistamines or decongestants in children. In a randomized trial, predeparture administration of <a class="drug drug_pediatric" data-topicid="12747" href="/z/d/drug information/12747.html" rel="external">pseudoephedrine</a> did not decrease ear pain but was associated with increased drowsiness [<a href="#rid28">28</a>]. In addition, decongestants and antihistamines may delay the resolution of middle ear fluid and have been associated with increased adverse effects in young children [<a href="#rid29">29-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Over-the-counter medications'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">ANTIBIOTIC THERAPY VERSUS OBSERVATION</span><span class="headingEndMark"> — </span>Strategies for initial management of AOM in children include immediate treatment with antibiotics and initial observation with delayed initiation of antibiotic therapy if the symptoms and signs worsen or fail to improve after 48 to 72 hours. Immediate antibiotic therapy hastens symptom resolution and reduces the occurrence of treatment failure, but it increases the occurrence of antibiotic-related side effects (diarrhea, rash).</p><p>The choice of strategy depends upon the severity of illness, the age of the child, associated conditions, and caregiver preference. Our approach is largely in agreement with that of the American Academy of Pediatrics and American Academy of Family Physicians for children age 6 months to 12 years [<a href="#rid1">1,32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children at increased risk of severe infection, complications, and/or recurrent AOM</strong> – Patients at increased risk of severe infection, complications, and/or recurrence include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &lt;6 months of age</p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are immunocompromised</p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are toxic appearing</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with craniofacial abnormalities (eg, cleft palate)</p><p></p><p class="bulletIndent1">For these patients, we recommend immediate antibiotic therapy rather than initial observation. Although children in these groups generally were excluded from clinical trials, it is reasonable to expect that immediate antibiotic therapy would have similar effects and that the anticipated absolute benefit would be greater in these children than in lower-risk patients. (See <a class="local">'Initial antibiotic therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children not at increased risk of severe infection, complications, and/or recurrent AOM</strong> – For most children not at increased risk of severe infection, complications, and/or recurrent AOM, we suggest immediate antibiotic therapy rather than initial observation. </p><p></p><p class="bulletIndent1">In randomized trials, antibiotic therapy hastened symptom resolution and reduced the likelihood of treatment failure. However, the absolute benefits are modest and antibiotic-related side effects are common (eg, diarrhea, rash). Thus, some families may reasonably choose initial observation over antibiotic therapy, particularly if the child is ≥2 years old and has unilateral AOM without severe symptoms or otorrhea. Initial antibiotic therapy is more likely to be selected for patients &lt;2 years old and those ≥2 years old with severe symptoms (eg, persistent ear pain for &gt;48 hours, temperature ≥39°C in the past 48 hours), bilateral AOM, otorrhea, or uncertain follow-up. (See <a class="local">'Initial antibiotic therapy'</a> below and <a class="local">'Initial observation'</a> below.)</p><p></p><p>Evidence from several trials suggest that many children with AOM do well with initial observation or with delayed antibiotics and analgesia and that the outcomes are similar among children with AOM who are treated with immediate versus delayed antibiotics [<a href="#rid9">9,11,33-35</a>]. However, immediate antibiotic therapy is associated with earlier resolution of symptoms and otoscopic findings, reduced risk of tympanic membrane perforation, reduced occurrence of treatment failure, and fewer missed days of work for caregivers [<a href="#rid36">36-42</a>].</p><p>In a 2023 meta-analysis of 13 trials, immediate antibiotics compared with placebo reduced the proportion of children with ear pain at two to three days (12 versus 16 percent; risk ratio [RR] 0.71, 95% CI 0.58-0.88 [7 trials, 2320 children]) [<a href="#rid9">9</a>]. In addition, antibiotic treatment reduced the number of tympanic membrane perforations (2 versus 5 percent; RR 0.43, 95% CI 0.21-0.89 [5 trials, 1075 children]) and the development of contralateral AOM (11 versus 19 percent; RR 0.49, 95% CI 0.25-0.95 [4 trials, 906 children]). Antibiotics also increased the risk of vomiting, diarrhea, and rash (27 versus 20 percent; RR 1.38, 95% CI 1.16-1.63 [8 trials, 2107 children]).</p><p>Immediate antibiotic therapy may be more beneficial for certain subgroups of children. In a meta-analysis of individual patient data from six trials (1643 children age 6 months to 12 years), antibiotics were most beneficial for children with AOM and otorrhea and children younger than two years with bilateral AOM [<a href="#rid6">6</a>]. Children younger than two years of age with unilateral AOM also appear to benefit from antibiotic therapy. Pooled analysis of two randomized trials that used stringent diagnostic criteria [<a href="#rid43">43,44</a>] found increased rates of treatment failure among placebo recipients &lt;24 months with unilateral, nonsevere AOM (40 versus 14 percent among antibiotic recipients; RR 0.34, 95% CI 0.18-0.65) [<a href="#rid42">42</a>]. Antibiotic therapy also reduced the rate of treatment failure in children with bilateral or severe (unilateral or bilateral) AOM (absolute risk reduction ranging from 31 to 34 percent), supporting the findings of earlier trials [<a href="#rid6">6,45,46</a>].</p><p class="headingAnchor" id="H10"><span class="h1">INITIAL ANTIBIOTIC THERAPY</span></p><p class="headingAnchor" id="H3472924874"><span class="h2">Preferred regimens</span><span class="headingEndMark"> — </span>Antibiotic therapy for AOM should include activity against the most common bacterial otopathogens: <em>Streptococcus pneumoniae</em>, nontypeable <em>Haemophilus influenzae</em> (NTHi), and <em>Moraxella catarrhalis</em>, and reflect current patterns of antimicrobial resistance. (See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Bacterial pathogens'</a>.)</p><p>We suggest <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> as the initial agents, depending upon the risk of beta-lactamase-producing NTHi.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for beta-lactamase-producing NTHi </strong>– Risk factors for beta-lactamase-producing NTHi include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Receipt of a beta-lactam antibiotic in the previous 30 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant purulent conjunctivitis (which is usually caused by NTHi)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of recurrent AOM unresponsive to <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> (NTHi is dominant in recurrent episodes)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Living in a community with high uptake of pneumococcal conjugate vaccine (PCV) in children [<a href="#rid47">47</a>]; in the United States, this information is available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fimz-managers%2Fcoverage%2Fchildvaxview%2Findex.html&amp;token=A9Ymtmr7XzJM4wLdcspeOrmEJRuLiHApHHlKMUumec%2FStO8GWrUKzGQIZsTHlSLPTrZYs5U%2BKnqjxq2hFNwWsf2QOIMAv0m8oMOPLSkWvkI%3D&amp;TOPIC_ID=5959" target="_blank">Centers for Disease Control and Prevention</a> [<a href="#rid48">48</a>]; in other countries, this information is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Fpages%2Fcoverage%2Fpcv.html&amp;token=2pWhlHMQRurSEI4DKUIbmegxNFfG3RLg3ZQwggGhfk%2B4VlakofK%2BANhpQjuvZZsicdR%2BdUspcQo%2B7Q9kvrdzng%3D%3D&amp;TOPIC_ID=5959" target="_blank">World Health Organization</a> [<a href="#rid49">49</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimen for children without risk factors </strong>– For children with AOM without risk factors for beta-lactamase-producing NTHi, we prefer <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> to other antibiotics  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Because of the increased prevalence of penicillin-nonsusceptible <em>S. pneumoniae</em> in the United States, we use a dose of 90 mg/kg per day orally divided in two doses (we suggest a maximum of 3 g/day) [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower doses of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> (eg, 40 mg/kg per day orally divided in two or three doses; maximum of 1.5 g/day) are appropriate in communities with low rates of penicillin-nonsusceptible <em>S. pneumoniae.</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimen for children at increased risk for beta-lactamase-producing NTHi</strong> – For children with AOM at increased risk for beta-lactamase-producing NTHi, we prefer <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> to other antibiotics  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>) [<a href="#rid52">52-55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In communities with increased prevalence of penicillin-resistant <em>S. pneumoniae</em>, we use a dose of 90 mg/kg per day of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> and 6.4 mg/kg per day of clavulanate orally divided in two doses (we suggest a maximum daily dose of the amoxicillin component of 3 g). Adolescents ≥16 years who can take large tablets can use extended-release <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> 1 to 2 g of amoxicillin and 62.5 to 125 mg of clavulanate orally every 12 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower doses of the <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> component (eg, 40 mg/kg of amoxicillin and 5.7 mg/kg of clavulanate orally divided in two doses) are appropriate in communities with lower rates of penicillin-nonsusceptible <em>S. pneumoniae</em>. However, the availability of <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> formulations with this ratio (7:1) of amoxicillin to clavulanate varies geographically.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – We treat with <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> for:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ten days for children &lt;2 years of age and children (of any age) with tympanic membrane perforation or history of recurrent AOM [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Five to seven days for children ≥2 years with intact tympanic membrane and no history of recurrent AOM [<a href="#rid57">57</a>].</p><p></p><p>Although other agents have efficacy comparable to <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> in randomized trials [<a href="#rid34">34</a>], we prefer amoxicillin for children at low risk for beta-lactamase-producing NTHi because it is effective, safe, relatively inexpensive, and has a narrow microbiologic spectrum [<a href="#rid1">1,58-60</a>]. Despite the increasing importance of NTHi (including beta-lactamase-producing strains) and<em> M. catarrhalis</em> as otopathogens in the post-PCV era [<a href="#rid61">61</a>], we continue to prefer high-dose amoxicillin to <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> for children at low risk for beta-lactamase-producing NTHi because some children with NTHi AOM recover without antibiotics, gastrointestinal adverse effects (eg, diarrhea, disturbance of the microbiome) are more common with amoxicillin-clavulanate, and, in observational studies, clinical failure rates were similar with narrow and broad spectrum antibiotics [<a href="#rid60">60,62-65</a>]. Other experts suggest amoxicillin-clavulanate as the initial antibiotic for all children with AOM [<a href="#rid64">64,66</a>]. (See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Bacterial pathogens'</a>.)</p><p>Using a dose of 90 mg/kg per day (high-dose) rather than 40 mg/kg per day (standard dose) increases the concentration of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> in the middle ear, which provides activity against most strains of <em>S. pneumoniae </em>with minimum inhibitory concentration (MIC) ≥2 and &lt;4 to penicillin [<a href="#rid67">67-69</a>]. <em>S. pneumoniae</em> that are highly resistant to penicillin in the United States (ie, MIC ≥8 mcg/mL), which account for &lt;2 percent of pneumococcal isolates, will not respond to high-dose amoxicillin [<a href="#rid1">1,70,71</a>]. Experience with strains with MIC &gt;4 and &lt;8 is limited.</p><p>High-dose <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> also may be more effective than standard-dose amoxicillin against ampicillin-susceptible NTHi.</p><p>Continued monitoring of the microbiology of AOM is necessary to determine when and if a change in preferred therapy is necessary. The increasing prevalence of beta-lactamase-negative, ampicillin-resistant strains of <em>H. influenzae</em> in the community is a potential concern. These strains exhibit MICs for <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> that may be at the upper limit of what is achievable in the middle ear. Such isolates remain uncommon in the United States but have become common in France and Japan [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Bacterial pathogens'</a>.)</p><p>We provide a 10-day course of antibiotics for children &lt;2 years of age and children (of any age) with tympanic membrane perforation or history of recurrent AOM. In a randomized trial, the clinical failure rate was lower with 10 than with 5 days of treatment with high-dose <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> for AOM in children age 6 through 23 months (16 versus 34 percent) [<a href="#rid56">56</a>]. Shorter courses are reasonable for children older than two years. In a meta-analysis of randomized trials in children age 1 month to 18 years, the clinical failure rate was only slightly lower with courses longer than seven days than with shorter courses (18 versus 21 percent), but longer courses were associated with increased rates of gastrointestinal adverse effects [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Alternative regimens</span><span class="headingEndMark"> — </span>Acceptable alternatives to <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> for children with penicillin allergy or who cannot otherwise tolerate penicillin antibiotics depend upon the type of the previous reaction  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef100745" href="/z/d/graphic/100745.html" rel="external">algorithm 2</a>). Alternative regimens may provide less activity against the spectrum of common otopathogens.</p><p>Clinical features and diagnosis of immediate and delayed penicillin allergy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild non-IgE-mediated reaction </strong>– Mild non-immunoglobulin E (IgE)-mediated reactions to penicillin typically appear after more than one dose (usually after days of treatment) and may be associated with a maculopapular or morbilliform eruption. They lack features of IgE-mediated reaction and serious delayed reactions  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a>.)</p><p></p><p class="bulletIndent1">For children with mild non-IgE-mediated reaction to penicillin antibiotics, we suggest one of the following  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral cephalosporins – For oral cephalosporins, we treat for 10 days in children &lt;2 years of age and children (of any age) with tympanic membrane perforation or recurrent AOM; we treat for 5 to 7 days in children ≥2 years of age with intact tympanic membrane and no history of recurrent AOM [<a href="#rid56">56,57</a>]. The availability of specific oral cephalosporins may vary regionally; appropriate alternatives (listed alphabetically) include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">Cefdinir</a> 14 mg/kg per day orally in one or two doses (maximum 600 mg/day)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">Cefpodoxime</a> 10 mg/kg per day orally in two doses (maximum 400 mg/day)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13137" href="/z/d/drug information/13137.html" rel="external">Cefuroxime</a> suspension (no longer available in the United States) 30 mg/kg per day orally divided in two doses (maximum 1 g/day)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="13137" href="/z/d/drug information/13137.html" rel="external">Cefuroxime</a> tablets 250 mg orally every 12 hours for children who weigh &gt;17 kg and can swallow the tablet whole</p><p></p><p class="bulletIndent2">The regimens above do not achieve sufficient concentration in the middle ear to eradicate penicillin-resistant <em>S. pneumoniae</em> and some penicillin-intermediate strains of <em>S. pneumoniae</em>. They have less activity against penicillin-resistant <em>S. pneumoniae</em> than <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> [<a href="#rid74">74</a>]. <a class="drug drug_pediatric" data-topicid="13137" href="/z/d/drug information/13137.html" rel="external">Cefuroxime</a> has less activity against beta-lactamase-producing NTHi than amoxicillin-clavulanate [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">Ceftriaxone</a> – Ceftriaxone 50 mg/kg intramuscularly (IM) once per day (maximum 1 g/day) for one to three doses (if there is symptomatic improvement within 48 hours of the first dose, additional doses are not necessary; if symptoms persist, a second and, if necessary, a third dose are administered [<a href="#rid75">75</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgE-mediated or serious delayed reaction</strong> – IgE-mediated reactions classically begin within one hour of the initial or last-administered dose; common features include anaphylaxis, angioedema, wheezing, laryngeal edema, hypotension, and hives/urticaria  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 2</a>). Delayed reactions appear after multiple doses of treatment. Examples of serious delayed reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug-induced cytopenias  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 2</a>) (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a>.)</p><p></p><p class="bulletIndent1">Alternatives to penicillin antibiotics for children with AOM and IgE-mediated or serious delayed reactions to penicillin or other beta-lactam antibiotics include macrolides (eg, <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>, <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>) or lincosamide (eg, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>) antibiotics  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>). However, these agents generally are not effective for eradication of <em>H. influenzae</em> and approximately 25 to 35 percent of <em>S. pneumoniae</em> isolates are resistant to macrolide or lincosamide antibiotics [<a href="#rid71">71,72,76,77</a>].</p><p></p><p class="bulletIndent1">The doses are as follows [<a href="#rid78">78</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">Azithromycin</a> 10 mg/kg per day orally (maximum 500 mg/day) as a single dose on day 1 and 5 mg/kg per day (maximum 250 mg/day) for days 2 through 5</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">Clarithromycin</a> 15 mg/kg per day orally divided into two doses (maximum 1 g/day)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">Clindamycin</a> 30 mg/kg per day orally divided into three doses (maximum 1.8 g/day)</p><p></p><p class="bulletIndent1">For <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a> and <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, we treat for 10 days in children &lt;2 years of age and children (of any age) with tympanic membrane perforation or recurrent AOM and for 5 to 7 days in children with intact tympanic membrane and no history of recurrent AOM [<a href="#rid56">56,57,79-82</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) may be useful in regions where pneumococcal resistance to TMP-SMX is not a concern, but TMP-SMX should not be used if group A <em>Streptococcus</em> (GAS; <em>Streptococcus pyogenes</em>) is suspected (eg, when there is an associated otorrhea). Local pneumococcal susceptibility data may be obtained from state or local health departments or local hospitals. (See <a class="local">'Tympanic membrane perforation'</a> below.)</p><p></p><p class="headingAnchor" id="H373199923"><span class="h2">Special circumstances</span></p><p class="headingAnchor" id="H3083937378"><span class="h3">Recurrent episode of AOM</span><span class="headingEndMark"> — </span>A recurrent episode of AOM is defined by the development of signs and symptoms of AOM after completion of successful treatment. As with the initial episode of AOM, bulging of the tympanic membrane or other signs of inflammation is crucial to the diagnosis  (<a class="graphic graphic_picture graphicRef63268" href="/z/d/graphic/63268.html" rel="external">picture 1</a>). This avoids unnecessary provision of antibiotics to children with persistent middle ear effusion. (See <a class="local">'Diagnosis of AOM'</a> above.)</p><p>There are no randomized trials to guide treatment of recurrent episodes of AOM in children. Our approach is based upon the microbiology of recurrent AOM in children. Antibiotic therapy for recurrent episodes of AOM must include coverage for resistant <em>S. pneumoniae</em>, NTHi<em>, </em>and<em> M. catarrhalis</em>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence within 15 days of completion of antimicrobial therapy </strong>– When recurrence occurs within 15 days of completion of antimicrobial treatment for the previous episode, it is most often due to persistence of the original pathogen.</p><p></p><p class="bulletIndent1">For children who were initially treated with <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>, we prefer <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>.</p><p></p><p class="bulletIndent1">For children who were initially treated with an antibiotic other than <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>, we suggest one of the following regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">Ceftriaxone</a> 50 mg/kg per day IM or intravenously (IV) for three days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">Ceftriaxone</a> 50 mg/kg per dose IM or IV every 36 hours for a total of two doses (although this regimen has not been studied, it is suggested based on pharmacokinetics and middle ear drug levels)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> 10 mg/kg orally once per day (maximum 750 mg/day) for 10 days is an alternative for children ≥8 years of age, but is rarely used [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence &gt;15 days after completion of antimicrobial therapy </strong>– Recurrence &gt;15 days after completion of treatment for the previous episode is most often due to a different pathogen than the previous episode. Recurrent AOM increases the likelihood of a pathogen nonsusceptible to <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>.</p><p></p><p class="bulletIndent1">Given the increased risk of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> nonsusceptibility, for children with recurrence &gt;15 days after completion of antimicrobial therapy for a previous episode, we suggest treatment with high-dose <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>, as described above. (See <a class="local">'Preferred regimens'</a> above.)</p><p></p><p>Tympanostomy tube insertion may be warranted for children with ≥3 distinct and well-documented episodes of AOM within 6 months or ≥4 episodes within 12 months if middle ear fluid is also present [<a href="#rid84">84</a>]. However, three strategies, tympanostomy tube insertion, antimicrobial prophylaxis, or episodic antimicrobial treatment, have similar outcomes [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence", section on 'Tympanostomy tubes'</a>.)</p><p>Evaluation of the immune system also may be warranted for children with ≥4 episodes of AOM within 12 months. However, if the spectrum of infection in the child is limited to recurrent AOM, a clinically concerning immune deficiency is unlikely. (See  <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">"Approach to the child with recurrent infections", section on 'Clinical features suggestive of a primary immunodeficiency'</a>.)</p><p class="headingAnchor" id="H49926436"><span class="h3">Tympanic membrane perforation</span><span class="headingEndMark"> — </span>For children with AOM and spontaneous tympanic membrane perforation, we suggest oral rather than topical antibiotic therapy. We prefer <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> to other oral agents. (See <a class="local">'Preferred regimens'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">Amoxicillin</a> 90 mg/kg per day orally divided in two doses (we suggest a maximum of 3 g/day) for 10 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">Amoxicillin-clavulanate</a> 90 mg/kg per day of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> and 6.4 mg/kg per day of clavulanate orally divided in two doses (we suggest a maximum daily dose of the amoxicillin component of 3 g) for 10 days. Adolescents ≥16 years who can take large tablets can use extended-release amoxicillin-clavulanate 1 to 2 g of amoxicillin and 62.5 to 125 mg of clavulanate orally every 12 hours.</p><p></p><p>For patients with acute otorrhea, 10 days of oral therapy is more effective than a shorter course [<a href="#rid86">86</a>].</p><p>Alternative agents for children with AOM and tympanic membrane perforation are the same as those for children without perforation, except that TMP-SMX should be avoided (given the frequency of GAS). (See <a class="local">'Alternative regimens'</a> above and  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Group A Streptococcus'</a>.)</p><p>Although topical therapy with quinolone otic drops (<a class="drug drug_pediatric" data-topicid="12962" href="/z/d/drug information/12962.html" rel="external">ofloxacin</a> or <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">ciprofloxacin</a>) is equivalent to oral therapy for treatment of otorrhea in children with tympanostomy tubes or chronic suppurative otitis media [<a href="#rid87">87,88</a>], topical therapy has not been studied in children with AOM and acute perforation [<a href="#rid87">87-89</a>]. For children with AOM and spontaneous perforation, we prefer oral therapy because the spontaneous perforation may heal quickly, limiting access of topical therapy to the middle ear. (See  <a class="medical medical_review" href="/z/d/html/6295.html" rel="external">"Tympanostomy tube otorrhea in children: Causes, prevention, and management", section on 'Treatment'</a> and <a class="local">'Tympanic membrane perforation'</a> below.)</p><p>In a systematic review of 19 studies describing the microbiology of AOM with discharge due to spontaneous perforation of the tympanic membrane in the post-PCV era, bacteria were isolated in 76 percent [<a href="#rid90">90</a>]. <em>S. pneumoniae</em> (median 26 percent) and <em>H. influenzae</em> (median 19 percent) were isolated most frequently, followed by <em>S. pyogenes</em> and <em>Staphylococcus aureus</em> (median for each 12 percent). Whether isolation of <em>S. aureus</em> from discharge in the external canal reflects pathogenicity or commensal bacteria is uncertain. Changes in antimicrobial susceptibility over time were not detected, although information about susceptibility was limited and predominantly related to <em>S. pneumoniae</em>.</p><p>Additional aspects of the management of tympanic membrane perforation are discussed below. (See <a class="local">'Tympanic membrane perforation'</a> below.)</p><p class="headingAnchor" id="H3878793740"><span class="h3">Otorrhea in children with tympanostomy tubes</span><span class="headingEndMark"> — </span>The treatment of otorrhea in children with tympanostomy tubes is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6295.html" rel="external">"Tympanostomy tube otorrhea in children: Causes, prevention, and management", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2513096898"><span class="h3">AOM in cochlear implant recipient</span><span class="headingEndMark"> — </span>Management of AOM in children with cochlear implants is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5534.html" rel="external">"Cochlear implant infections", section on 'Management'</a>.)</p><p class="headingAnchor" id="H49925565"><span class="h1">INITIAL OBSERVATION</span><span class="headingEndMark"> — </span>When the initial observation strategy is chosen, caregivers must understand the risks and benefits, and appropriate follow-up must be ensured so that antibiotic therapy can be initiated if symptoms worsen or persist after 48 to 72 hours [<a href="#rid1">1</a>]. Unilateral AOM at first observation may rapidly progress to bilateral disease during the subsequent hours of illness.</p><p>Appropriate follow-up may include [<a href="#rid37">37,38,91-94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Caregiver-initiated visit or phone contact if symptoms worsen or do not improve at 48 to 72 hours</p><p class="bulletIndent1"><span class="glyph">●</span>A scheduled follow-up appointment in 48 to 72 hours</p><p></p><p>Specific indications for urgent follow-up (eg, signs of meningismus, cranial nerve palsy) should be provided to patients or caregivers and documented in the medical record. (See <a class="local">'Response to antibiotics or observation'</a> below.)</p><p class="headingAnchor" id="H49926213"><span class="h1">RESPONSE TO ANTIBIOTICS OR OBSERVATION</span></p><p class="headingAnchor" id="H49926240"><span class="h2">Persistent symptoms</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial observation </strong>– Children who worsen during observation or fail to improve after 48 to 72 hours of observation should be started on antibiotics.<em> </em>The child's status should be carefully reassessed in person (or by telehealth if the caregiver is well known to the clinician or office to determine if in-person re-evaluation is needed) before initiating antimicrobial treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial antibiotic therapy</strong> – Failure to improve or worsening after 48 to 72 hours of antibiotic therapy and analgesic therapy is considered treatment failure. Evaluation and management of treatment failure is discussed below. (See <a class="local">'Treatment failure'</a> below.)</p><p></p><p class="headingAnchor" id="H49926247"><span class="h2">Resolution of symptoms</span><span class="headingEndMark"> — </span>Children whose symptoms have resolved should have follow-up to monitor the resolution of the associated middle ear effusion, which is associated with conductive hearing loss.</p><p class="bulletIndent1"><span class="glyph">●</span>For children &lt;2 years of age and children ≥2 years of age with language or learning problems, we suggest follow-up otoscopy 8 to 12 weeks after diagnosis of AOM; for children ≤2 years, this timeframe may coincide with a previously scheduled health maintenance visit.</p><p></p><p class="bulletIndent1">By 8 to 12 weeks after the diagnosis of AOM, the middle ear effusion will have resolved in 80 to 90 percent of children  (<a class="graphic graphic_figure graphicRef81406" href="/z/d/graphic/81406.html" rel="external">figure 1</a>). (See <a class="local">'Clinical course without antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children ≥2 years without language or learning problems, we provide follow-up at the next health maintenance visit, or sooner if there are concerns regarding persistent hearing loss.</p><p></p><p>Although persistent middle ear fluid requires monitoring after resolution of symptoms, it is not an indication of treatment failure or an indication for additional antibiotic therapy [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/z/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management", section on 'Approach to management'</a> and <a class="local">'Clinical course without antibiotics'</a> above.)</p><p class="headingAnchor" id="H49927983"><span class="h1">TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Worsening during, or failure to improve after, 48 to 72 hours of antibiotic therapy and analgesic therapy is considered treatment failure.</p><p class="headingAnchor" id="H1836032472"><span class="h2">Etiology</span><span class="headingEndMark"> — </span>Treatment failure suggests either:</p><p class="bulletIndent1"><span class="glyph">●</span>Development of a complication (see  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Complications and sequelae'</a> and <a class="local">'Management of AOM complications'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial antimicrobial therapy was inadequate</p><p></p><p class="bulletIndent1">Although inadequate therapy is usually related to infection with an organism resistant to beta-lactam antibiotics (eg, nontypeable <em>H. influenzae</em> [NTHi], drug-resistant <em>S. pneumoniae</em>), infection with less common organisms, such as <em>S. aureus</em>, also must be considered, particularly in children with tympanostomy tubes or perforation [<a href="#rid90">90,96-101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Microbiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another disease is present (see  <a class="medical medical_review" href="/z/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>)</p><p></p><p class="headingAnchor" id="H3389431417"><span class="h2">Changes to antibiotic regimen</span><span class="headingEndMark"> — </span>Our approach to antimicrobial therapy for treatment failure varies with the initial agent, as described below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial </strong><strong>amoxicillin</strong> – For children who fail initial treatment with high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>, we prefer <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">Amoxicillin-clavulanate</a> 90 mg/kg per day <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> and 6.4 mg/kg day of clavulanate orally divided in two doses (we suggest a maximum of 3 g/day). Adolescents ≥16 years who can take large tablets can use extended-release amoxicillin-clavulanate 1 to 2 g of the amoxicillin component and 62.5 to 125 mg of the clavulanate component every 12 hours.</p><p></p><p class="bulletIndent2">We treat for 10 days in children &lt;2 years of age and children (of any age) with tympanic membrane perforation or recurrent AOM; we treat for 5 to 7 days in children ≥2 years of age with intact tympanic membrane and no history of recurrent AOM [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent2">We prefer <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> for children who fail treatment with <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> because of amoxicillin-clavulanate's efficacy against beta-lactamase-producing <em>H. influenzae</em> and <em>M. catarrhalis</em>; for <em>S. pneumoniae</em>, amoxicillin and amoxicillin-clavulanate have equivalent efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial </strong><strong>amoxicillin-clavulanate</strong><strong> or oral cephalosporins</strong> – For children who fail initial treatment with high-dose <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> or oral cephalosporins, we prefer parenteral <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>; oral <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a> is an alternative  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">Ceftriaxone</a> 50 mg/kg intramuscularly or intravenously once per day (maximum 1g/day) for two or three doses.</p><p></p><p class="bulletIndent2">Parenteral <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> 50 mg/kg achieves high levels in the middle ear and is effective for the treatment of AOM in children who fail <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> [<a href="#rid1">1</a>]. An open-label prospective study suggested that three doses were superior to a single dose in eradicating penicillin-resistant <em>S. pneumoniae</em> from the middle ear [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age 6 months to 5 years – 10 mg/kg orally every 12 hours for 10 days</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age ≥5 years – 10 mg/kg per orally once daily (maximum 750 mg/day) for 10 days [<a href="#rid83">83</a>]</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> should be reserved for children with contraindications to <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or AOM refractory to other drugs (ideally it should only be used in children who have had serotype 19A isolated from the middle ear that is susceptible to levofloxacin) [<a href="#rid96">96</a>]. Levofloxacin resistance among <em>S. pneumoniae</em> respiratory isolates has been described in adults and rarely in children [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX), macrolides (eg, <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>, <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>), and lincosamides (eg, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>) are not recommended for AOM that fails to respond to treatment with high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>. Pneumococcal surveillance studies indicate that resistance to these agents is substantial [<a href="#rid104">104,105</a>]. Macrolides and lincosamides have limited activity against NTHi, which is a more likely pathogen among children who have failed initial amoxicillin therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial macrolides, </strong><strong>clindamycin</strong><strong>, or parenteral </strong><strong>ceftriaxone</strong><strong> or persistent treatment failure</strong> – Persistent treatment failure is defined by failure to improve after 48 to 72 hours of the second antibiotic.</p><p></p><p class="bulletIndent1">For children who fail initial treatment with macrolides, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, or parenteral <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> and children with persistent treatment failure, we prefer tympanocentesis, if available, for culture and susceptibility of middle ear fluid to guide antimicrobial selection. Tympanocentesis will also provide relief of ear pain. A discussion of the tympanocentesis procedure is beyond the scope of this topic review but is available in the full text of reference [<a href="#rid106">106</a>]. Concomitant placement of a tympanostomy tube may be warranted. (See  <a class="medical medical_review" href="/z/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence", section on 'Tympanostomy tubes'</a>.)</p><p></p><p class="bulletIndent1">If tympanocentesis is not available, switching to <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a> is reasonable [<a href="#rid83">83</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age 6 months to 5 years – 10 mg/kg orally every 12 hours for 10 days</p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥5 years – 10 mg/kg per orally once daily (maximum 750 mg/day) for 10 days</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> generally should be reserved for children with contraindications to <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or AOM refractory to other drugs (ideally it should only be used in children who have had serotype 19A isolated from the middle ear that is susceptible to levofloxacin) [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1">The pathogens most likely in this scenario are multidrug-resista<em>nt S. pneumoniae </em>or NTHi (either beta-lactamase positive or beta-lactamase negative). Most NTHi are susceptible to TMP-SMX, but susceptibility of <em>S. pneumoniae</em> varies geographically. TMP-SMX may be an option in areas with high rates of susceptibility.</p><p></p><p class="bulletIndent1">Consultation with a pediatric infectious diseases expert and/or pediatric otolaryngologist may be warranted  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H3751217306"><span class="h1">MANAGEMENT OF AOM COMPLICATIONS</span></p><p class="headingAnchor" id="H4114214245"><span class="h2">Tympanic membrane perforation</span><span class="headingEndMark"> — </span>Tympanic membrane perforation permits drainage of the middle ear abscess and relieves increased middle ear pressure. With the relief of middle ear pressure, the tympanic membrane usually heals quickly, sealing the perforation in hours to days. Antimicrobial therapy for children with tympanic membrane perforation is discussed above. (See <a class="local">'Tympanic membrane perforation'</a> above.)</p><p>Pain or persistent ear pain in a child with AOM and tympanic membrane perforation is unlikely to be due to AOM because the increased pressure in the middle is relieved with the perforation. Other causes of ear pain include:</p><p class="bulletIndent1"><span class="glyph">●</span>Extension of the infection to a contiguous space, such as the mastoid (ie, mastoiditis) (see  <a class="medical medical_review" href="/z/d/html/6062.html" rel="external">"Acute mastoiditis in children: Clinical features and diagnosis", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irritation of the external canal from middle ear drainage, resulting in otitis externa, in which case treatment with a topical quinolone may be beneficial (see  <a class="medical medical_review" href="/z/d/html/16516.html" rel="external">"External otitis: Treatment", section on 'Topical otic preparations: General principles'</a>)</p><p></p><p>Nonantimicrobial topical agents, such as <a class="drug drug_pediatric" data-topicid="13008" href="/z/d/drug information/13008.html" rel="external">benzocaine</a> or olive oil, should not be used to treat pain in patients with perforation of the tympanic membrane. These agents are not effective and may be harmful.</p><p>Patients with perforation that persists for three months or longer (with or without suppurative drainage) should be referred to an otolaryngologist for further management [<a href="#rid107">107</a>]. Prevention of chronic suppurative otitis media (CSOM) entails promptly treating AOM, given that CSOM frequently begins with an episode of AOM [<a href="#rid108">108</a>]. (See  <a class="medical medical_review" href="/z/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention"</a>.)</p><p class="headingAnchor" id="H4191160837"><span class="h2">Other complications</span><span class="headingEndMark"> — </span>The management of other intratemporal or intracranial complications of AOM is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Cholesteatoma (see  <a class="medical medical_review" href="/z/d/html/6306.html" rel="external">"Cholesteatoma in children", section on 'Surgical treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mastoiditis, which may be complicated by petrositis (osteomyelitis of the petrous bone) (see  <a class="medical medical_review" href="/z/d/html/6036.html" rel="external">"Acute mastoiditis in children: Treatment and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Facial nerve palsy, which may be isolated or associated with osteomyelitis of the petrous bone (see  <a class="medical medical_review" href="/z/d/html/6217.html" rel="external">"Facial nerve palsy in children", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/6036.html" rel="external">"Acute mastoiditis in children: Treatment and prevention", section on 'Complicated disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningitis (see  <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">"Bacterial meningitis in children older than one month: Treatment and prognosis"</a>)</p><p></p><p class="headingAnchor" id="H397878011"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109085.html" rel="external">"Society guideline links: Acute otitis media, otitis media with effusion, and external otitis"</a>.)</p><p class="headingAnchor" id="H10149544"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15373.html" rel="external">"Patient education: Ear infections in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/17229.html" rel="external">"Patient education: Ruptured eardrum (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1204.html" rel="external">"Patient education: Ear infections (otitis media) in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain management</strong> – Pain management is a mainstay of treatment for AOM in children. For most patients, we suggest oral <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> or <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> rather than other analgesics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative analgesic agents for children ≥2 years of age without tympanic membrane perforation include topical procaine or <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> preparations (if available). (See <a class="local">'Management of pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate antibiotics versus observation</strong> – The choice of immediate treatment with antibiotics or observation depends upon the severity of illness, the age of the child, associated conditions, and caregiver preference (see <a class="local">'Antibiotic therapy versus observation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients at increased risk of severe infection, complications, and/or recurrent AOM</strong> – Patients at increased risk of severe infection, complications, and/or recurrence include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Infants &lt;6 months of age</p><p class="bulletIndent3"><span class="glyph">-</span>Patients who are immunocompromised</p><p class="bulletIndent3"><span class="glyph">-</span>Patients who are toxic appearing</p><p class="bulletIndent3"><span class="glyph">-</span>Patients with craniofacial abnormalities (eg, cleft palate)</p><p></p><p class="bulletIndent2">For these patients, we recommend immediate antibiotic therapy rather than initial observation (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Initial antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children not at increased risk of severe infection, complications, and/or recurrent AOM</strong> – For most children not at increased risk of severe infection, complications, and/or recurrent AOM, we suggest immediate antibiotic therapy rather than initial observation (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>).</p><p></p><p class="bulletIndent2">In randomized trials, antibiotic therapy hastened symptom resolution and reduced the likelihood of treatment failure. However, the absolute benefits are modest and antibiotic-related side effects are common (eg, diarrhea, rash). Thus, some families may reasonably choose initial observation over antibiotic therapy, particularly if the child is ≥2 years old and has unilateral AOM without severe symptoms or otorrhea. Initial antibiotic therapy is more likely to be selected for patients &lt;2 years old and those ≥2 years old with severe symptoms (eg, persistent ear pain for &gt;48 hours, temperature ≥39°C in the past 48 hours), bilateral AOM, otorrhea, or uncertain follow-up. (See <a class="local">'Initial antibiotic therapy'</a> above and <a class="local">'Initial observation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimens</strong> – Antibiotic therapy for AOM should include activity against the most common bacterial otopathogens: <em>Streptococcus pneumoniae</em>, nontypeable <em>Haemophilus influenzae</em> (NTHi), and <em>Moraxella catarrhalis</em>, considering changes in resistance patterns over time. (See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Bacterial pathogens'</a>.)</p><p></p><p class="bulletIndent1">When antibiotic treatment is warranted for the treatment of AOM in children, we suggest <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> rather than other antibiotics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); the choice between these agents depends upon the risk of beta-lactamase-producing NTHi. Alternative regimens (eg, oral, <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">cefdinir</a>, <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">cefpodoxime</a>, <a class="drug drug_pediatric" data-topicid="13137" href="/z/d/drug information/13137.html" rel="external">cefuroxime</a>, <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>, <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>, or <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>; intramuscular <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>) may provide less activity against the spectrum of common otopathogens  (<a class="graphic graphic_algorithm graphicRef116756" href="/z/d/graphic/116756.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>). (See <a class="local">'Preferred regimens'</a> above and <a class="local">'Alternative regimens'</a> above.)</p><p></p><p class="bulletIndent1">The dose for <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> depends upon the local prevalence of penicillin-nonsusceptible <em>S. pneumoniae</em>  (<a class="graphic graphic_table graphicRef76491" href="/z/d/graphic/76491.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to initial management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial observation – Patients whose symptoms worsen or fail to improve after 48 to 72 hours of observation usually warrant antibiotics. (See <a class="local">'Persistent symptoms'</a> above and <a class="local">'Preferred regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial antibiotics – Worsening during, or failure to improve after, 48 to 72 hours of antibiotic therapy and analgesic therapy is considered treatment failure. Causes of treatment failure include development of a complication, inadequate initial antimicrobial therapy, or a condition other than AOM. (See <a class="local">'Treatment failure'</a> above and <a class="local">'Management of AOM complications'</a> above and  <a class="medical medical_review" href="/z/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H340053689"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Jerome Klein, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131:e964.</a></li><li><a class="nounderline abstract_t">Shaikh N, Hoberman A, Rockette HE, Kurs-Lasky M. Development of an algorithm for the diagnosis of otitis media. Acad Pediatr 2012; 12:214.</a></li><li><a class="nounderline abstract_t">Tähtinen PA, Laine MK, Ruohola A. Prognostic Factors for Treatment Failure in Acute Otitis Media. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Palmu AA, Herva E, Savolainen H, et al. Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis 2004; 38:234.</a></li><li><a class="nounderline abstract_t">McCormick DP, Lim-Melia E, Saeed K, et al. Otitis media: can clinical findings predict bacterial or viral etiology? Pediatr Infect Dis J 2000; 19:256.</a></li><li><a class="nounderline abstract_t">Rovers MM, Glasziou P, Appelman CL, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006; 368:1429.</a></li><li><a class="nounderline abstract_t">Venekamp RP, Sanders SL, Glasziou PP, et al. Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2015; :CD000219.</a></li><li><a class="nounderline abstract_t">Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013; 347:f7027.</a></li><li><a class="nounderline abstract_t">Venekamp RP, Sanders SL, Glasziou PP, Rovers MM. Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2023; 11:CD000219.</a></li><li><a class="nounderline abstract_t">Teele DW, Klein JO, Rosner BA. Epidemiology of otitis media in children. Ann Otol Rhinol Laryngol Suppl 1980; 89:5.</a></li><li><a class="nounderline abstract_t">Ruohola A, Laine MK, Tähtinen PA. Effect of Antimicrobial Treatment on the Resolution of Middle-Ear Effusion After Acute Otitis Media. J Pediatric Infect Dis Soc 2018; 7:64.</a></li><li><a class="nounderline abstract_t">Steele DW, Adam GP, Di M, et al. Effectiveness of Tympanostomy Tubes for Otitis Media: A Meta-analysis. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Tapiainen T, Kujala T, Renko M, et al. Effect of antimicrobial treatment of acute otitis media on the daily disappearance of middle ear effusion: a placebo-controlled trial. JAMA Pediatr 2014; 168:635.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Otitis media (acute): antimicrobial prescribing. March, 2018. Available at: https://www.nice.org.uk/guidance/ng91 (Accessed on August 11, 2021).</li><li><a class="nounderline abstract_t">Hoberman A, Paradise JL, Reynolds EA, Urkin J. Efficacy of Auralgan for treating ear pain in children with acute otitis media. Arch Pediatr Adolesc Med 1997; 151:675.</a></li><li><a class="nounderline abstract_t">Bolt P, Barnett P, Babl FE, Sharwood LN. Topical lignocaine for pain relief in acute otitis media: results of a double-blind placebo-controlled randomised trial. Arch Dis Child 2008; 93:40.</a></li><li class="breakAll">Questions &amp; Answers: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth www.fda.gov/Drugs/DrugSafety/ucm250029.htm (Accessed on August 03, 2012).</li><li><a class="nounderline abstract_t">de Sévaux JLH, Damoiseaux RA, van de Pol AC, et al. Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. Cochrane Database Syst Rev 2023; 8:CD011534.</a></li><li><a class="nounderline abstract_t">Foxlee R, Johansson A, Wejfalk J, et al. Topical analgesia for acute otitis media. Cochrane Database Syst Rev 2006; :CD005657.</a></li><li><a class="nounderline abstract_t">Roddey OF Jr, Earle R Jr, Haggerty R. Myringotomy in acute otitis media. A controlled study. JAMA 1966; 197:849.</a></li><li><a class="nounderline abstract_t">Pichichero ME, Casey JR, Almudevar A. Reducing the frequency of acute otitis media by individualized care. Pediatr Infect Dis J 2013; 32:473.</a></li><li><a class="nounderline abstract_t">Pichichero ME. Shortened Antimicrobial Treatment for Acute Otitis Media. N Engl J Med 2017; 376:e24.</a></li><li><a class="nounderline abstract_t">Morgagni F, Autore A, Landolfi A, et al. Predictors of ear barotrauma in aircrews exposed to simulated high altitude. Aviat Space Environ Med 2012; 83:594.</a></li><li><a class="nounderline abstract_t">Otalgia in infants traveling in airplanes. N Engl J Med 1983; 308:781.</a></li><li><a class="nounderline abstract_t">Ishiyama A. Why does air travel cause earache? West J Med 1999; 171:106.</a></li><li><a class="nounderline abstract_t">Bettes TN, McKenas DK. Medical advice for commercial air travelers. Am Fam Physician 1999; 60:801.</a></li><li><a class="nounderline abstract_t">Stangerup SE, Tjernström O, Harcourt J, et al. Barotitis in children after aviation; prevalence and treatment with Otovent. J Laryngol Otol 1996; 110:625.</a></li><li><a class="nounderline abstract_t">Buchanan BJ, Hoagland J, Fischer PR. Pseudoephedrine and air travel-associated ear pain in children. Arch Pediatr Adolesc Med 1999; 153:466.</a></li><li><a class="nounderline abstract_t">Coleman C, Moore M. Decongestants and antihistamines for acute otitis media in children. Cochrane Database Syst Rev 2008; :CD001727.</a></li><li><a class="nounderline abstract_t">Chonmaitree T, Saeed K, Uchida T, et al. A randomized, placebo-controlled trial of the effect of antihistamine or corticosteroid treatment in acute otitis media. J Pediatr 2003; 143:377.</a></li><li><a class="nounderline abstract_t">Pappas DE, Hendley JO. The common cold and decongestant therapy. Pediatr Rev 2011; 32:47.</a></li><li class="breakAll">American Academy of Pediatrics. Systems-based treatment table. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.990.</li><li><a class="nounderline abstract_t">Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. J Pediatr 1994; 124:355.</a></li><li><a class="nounderline abstract_t">Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010; 304:2161.</a></li><li><a class="nounderline abstract_t">Shekelle PG, Takata G, Newberry SJ, et al. Management of Acute Otitis Media: update. Evid Rep Technol Assess (Full Rep) 2010; :1.</a></li><li><a class="nounderline abstract_t">McCormick DP, Chonmaitree T, Pittman C, et al. Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment. Pediatrics 2005; 115:1455.</a></li><li><a class="nounderline abstract_t">Spiro DM, Tay KY, Arnold DH, et al. Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial. JAMA 2006; 296:1235.</a></li><li><a class="nounderline abstract_t">Little P, Gould C, Williamson I, et al. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001; 322:336.</a></li><li><a class="nounderline abstract_t">Little P, Moore M, Warner G, et al. Longer term outcomes from a randomised trial of prescribing strategies in otitis media. Br J Gen Pract 2006; 56:176.</a></li><li><a class="nounderline abstract_t">Tähtinen PA, Laine MK, Ruuskanen O, Ruohola A. Delayed versus immediate antimicrobial treatment for acute otitis media. Pediatr Infect Dis J 2012; 31:1227.</a></li><li><a class="nounderline abstract_t">Spurling GK, Del Mar CB, Dooley L, et al. Delayed antibiotic prescriptions for respiratory infections. Cochrane Database Syst Rev 2017; 9:CD004417.</a></li><li><a class="nounderline abstract_t">Hoberman A, Ruohola A, Shaikh N, et al. Acute otitis media in children younger than 2 years. JAMA Pediatr 2013; 167:1171.</a></li><li><a class="nounderline abstract_t">Tähtinen PA, Laine MK, Huovinen P, et al. A placebo-controlled trial of antimicrobial treatment for acute otitis media. N Engl J Med 2011; 364:116.</a></li><li><a class="nounderline abstract_t">Hoberman A, Paradise JL, Rockette HE, et al. Treatment of acute otitis media in children under 2 years of age. N Engl J Med 2011; 364:105.</a></li><li><a class="nounderline abstract_t">Kaleida PH, Casselbrant ML, Rockette HE, et al. Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial. Pediatrics 1991; 87:466.</a></li><li><a class="nounderline abstract_t">Rovers MM, Glasziou P, Appelman CL, et al. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: a meta-analysis of individual patient data. Pediatrics 2007; 119:579.</a></li><li><a class="nounderline abstract_t">Kaur R, Fuji N, Pichichero ME. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019. Eur J Clin Microbiol Infect Dis 2022; 41:37.</a></li><li class="breakAll">Centers for Disease Control and Prevention. ChildVaxView. Available at: https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/index.html (Accessed on June 08, 2022).</li><li class="breakAll">World Health Organization. Pneumococcal vaccination coverage. Available at: https://immunizationdata.who.int/pages/coverage/pcv.html (Accessed on June 08, 2022).</li><li><a class="nounderline abstract_t">Thanaviratananich S, Laopaiboon M, Vatanasapt P. Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media. Cochrane Database Syst Rev 2013; :CD004975.</a></li><li><a class="nounderline abstract_t">Dagan R. The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media. Int J Antimicrob Agents 2007; 30 Suppl 2:S127.</a></li><li><a class="nounderline abstract_t">Wald ER, Mason EO Jr, Bradley JS, et al. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Pediatr Infect Dis J 2001; 20:34.</a></li><li><a class="nounderline abstract_t">Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediatr Adolesc Med 1999; 153:495.</a></li><li><a class="nounderline abstract_t">Chung A, Perera R, Brueggemann AB, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ 2007; 335:429.</a></li><li><a class="nounderline abstract_t">Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012; 31:249.</a></li><li><a class="nounderline abstract_t">Hoberman A, Paradise JL, Rockette HE, et al. Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children. N Engl J Med 2016; 375:2446.</a></li><li><a class="nounderline abstract_t">Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. Cochrane Database Syst Rev 2010; :CD001095.</a></li><li><a class="nounderline abstract_t">Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1.</a></li><li><a class="nounderline abstract_t">Shaikh N, Dando EE, Dunleavy ML, et al. A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. J Pediatr 2017; 189:54.</a></li><li><a class="nounderline abstract_t">Frost HM, Gerber JS, Hersh AL. Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis. Pediatr Infect Dis J 2019; 38:217.</a></li><li><a class="nounderline abstract_t">Kaur R, Morris M, Pichichero ME. Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Gerber JS, Ross RK, Bryan M, et al. Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections. JAMA 2017; 318:2325.</a></li><li><a class="nounderline abstract_t">Hum SW, Shaikh KJ, Musa SS, Shaikh N. Adverse Events of Antibiotics Used to Treat Acute Otitis Media in Children: A Systematic Meta-Analysis. J Pediatr 2019; 215:139.</a></li><li><a class="nounderline abstract_t">Pichichero ME. Considering an otitis media antibiotic change. J Pediatr 2020; 222:253.</a></li><li><a class="nounderline abstract_t">Frost HM, Bizune D, Gerber JS, et al. Amoxicillin Versus Other Antibiotic Agents for the Treatment of Acute Otitis Media in Children. J Pediatr 2022; 251:98.</a></li><li><a class="nounderline abstract_t">Wald ER, DeMuri GP. Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis: Conundrum No More. Pediatr Infect Dis J 2018; 37:1255.</a></li><li><a class="nounderline abstract_t">Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1997; 16:710.</a></li><li><a class="nounderline abstract_t">Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009; 48:1596.</a></li><li class="breakAll">National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Tenth informational supplement M100-S10, National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania 2000.</li><li><a class="nounderline abstract_t">Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999; 43:1901.</a></li><li><a class="nounderline abstract_t">Lee GM, Kleinman K, Pelton S, et al. Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007; 20:368.</a></li><li><a class="nounderline abstract_t">Yamada S, Seyama S, Wajima T, et al. β-Lactamase-non-producing ampicillin-resistant Haemophilus influenzae is acquiring multidrug resistance. J Infect Public Health 2020; 13:497.</a></li><li><a class="nounderline abstract_t">Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 Suppl 1:S13.</a></li><li><a class="nounderline abstract_t">Klein JO. Review of consensus reports on management of acute otitis media. Pediatr Infect Dis J 1999; 18:1152.</a></li><li><a class="nounderline abstract_t">Critchley IA, Jacobs MR, Brown SD, et al. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. Antimicrob Agents Chemother 2008; 52:2639.</a></li><li><a class="nounderline abstract_t">Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 2008; 6:619.</a></li><li class="breakAll">American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.</li><li><a class="nounderline abstract_t">Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997; 16:463.</a></li><li><a class="nounderline abstract_t">Pessey JJ, Gehanno P, Thoroddsen E, et al. Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate. Pediatr Infect Dis J 1999; 18:854.</a></li><li><a class="nounderline abstract_t">Cohen R, Levy C, Chalumeau M. Shortened Antimicrobial Treatment for Acute Otitis Media. N Engl J Med 2017; 376:e24.</a></li><li><a class="nounderline abstract_t">Kenna MA. Acute Otitis Media - The Long and the Short of It. N Engl J Med 2016; 375:2492.</a></li><li><a class="nounderline abstract_t">Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J 2006; 25:1102.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Tunkel DE, Schwartz SR, et al. Clinical Practice Guideline: Tympanostomy Tubes in Children (Update). Otolaryngol Head Neck Surg 2022; 166:S1.</a></li><li><a class="nounderline abstract_t">Hoberman A, Preciado D, Paradise JL, et al. Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media. N Engl J Med 2021; 384:1789.</a></li><li><a class="nounderline abstract_t">Hendrickse WA, Kusmiesz H, Shelton S, Nelson JD. Five vs. ten days of therapy for acute otitis media. Pediatr Infect Dis J 1988; 7:14.</a></li><li><a class="nounderline abstract_t">Goldblatt EL, Dohar J, Nozza RJ, et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngol 1998; 46:91.</a></li><li><a class="nounderline abstract_t">Suzuki K, Nishimura T, Baba S, et al. Topical ofloxacin for chronic suppurative otitis media and acute exacerbation of chronic otitis media: optimum duration of treatment. Otol Neurotol 2003; 24:447.</a></li><li><a class="nounderline abstract_t">Venekamp RP, Prasad V, Hay AD. Are topical antibiotics an alternative to oral antibiotics for children with acute otitis media and ear discharge? BMJ 2016; 352:i308.</a></li><li><a class="nounderline abstract_t">Hullegie S, Venekamp RP, van Dongen TMA, et al. Prevalence and Antimicrobial Resistance of Bacteria in Children With Acute Otitis Media and Ear Discharge: A Systematic Review. Pediatr Infect Dis J 2021; 40:756.</a></li><li><a class="nounderline abstract_t">Siegel RM, Kiely M, Bien JP, et al. Treatment of otitis media with observation and a safety-net antibiotic prescription. Pediatrics 2003; 112:527.</a></li><li><a class="nounderline abstract_t">Chao JH, Kunkov S, Reyes LB, et al. Comparison of two approaches to observation therapy for acute otitis media in the emergency department. Pediatrics 2008; 121:e1352.</a></li><li><a class="nounderline abstract_t">Uitti JM, Tähtinen PA, Laine MK, Ruohola A. Close Follow-up in Children With Acute Otitis Media Initially Managed Without Antimicrobials. JAMA Pediatr 2016; 170:1107.</a></li><li><a class="nounderline abstract_t">Cates C. An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study. BMJ 1999; 318:715.</a></li><li class="breakAll">Bluestone CD, Klein JO. Management. In: Otitis Media in Infants and Children, 4th ed, BC Decker, Hamilton, ON 2007. p.213.</li><li><a class="nounderline abstract_t">Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298:1772.</a></li><li><a class="nounderline abstract_t">Cilveti R, Olmo M, Pérez-Jove J, et al. Epidemiology of Otitis Media with Spontaneous Perforation of the Tympanic Membrane in Young Children and Association with Bacterial Nasopharyngeal Carriage, Recurrences and Pneumococcal Vaccination in Catalonia, Spain - The Prospective HERMES Study. PLoS One 2017; 12:e0170316.</a></li><li><a class="nounderline abstract_t">Sonsuwan N, Watcharinyanon P, Sawanyawisuth K. What are the leading causative pathogens in acute otitis media with tympanic membrane perforation? Int J Pediatr Otorhinolaryngol 2016; 90:20.</a></li><li><a class="nounderline abstract_t">Marchisio P, Esposito S, Picca M, et al. Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation. Clin Microbiol Infect 2017; 23:486.e1.</a></li><li><a class="nounderline abstract_t">Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005; 131:782.</a></li><li><a class="nounderline abstract_t">Santos F, Mankarious LA, Eavey RD. Methicillin-resistant Staphylococcus aureus: pediatric otitis. Arch Otolaryngol Head Neck Surg 2000; 126:1383.</a></li><li><a class="nounderline abstract_t">Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19:1040.</a></li><li><a class="nounderline abstract_t">Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004; 48:3491.</a></li><li><a class="nounderline abstract_t">Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63:511.</a></li><li><a class="nounderline abstract_t">Sader HS, Mendes RE, Le J, et al. Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). Open Forum Infect Dis 2019; 6:S14.</a></li><li><a class="nounderline abstract_t">Shaikh N, Hoberman A, Kearney DH, Yellon R. Videos in clinical medicine. Tympanocentesis in children with acute otitis media. N Engl J Med 2011; 364:e4.</a></li><li><a class="nounderline abstract_t">Bluestone CD. Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J 2000; 19:S37.</a></li><li><a class="nounderline abstract_t">Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otorhinolaryngol 1998; 42:207.</a></li></ol></div><div id="topicVersionRevision">Topic 5959 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439909" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The diagnosis and management of acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459064" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Development of an algorithm for the diagnosis of otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28790141" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prognostic Factors for Treatment Failure in Acute Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699456" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of clinical signs and symptoms with bacterial findings in acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749473" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Otitis media: can clinical findings predict bacterial or viral etiology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17055944" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antibiotics for acute otitis media: a meta-analysis with individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26099233" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotics for acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24335668" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Duration of symptoms of respiratory tract infections in children: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37965923" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotics for acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6778349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28340091" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of Antimicrobial Treatment on the Resolution of Middle-Ear Effusion After Acute Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562283" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effectiveness of Tympanostomy Tubes for Otitis Media: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797294" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of antimicrobial treatment of acute otitis media on the daily disappearance of middle ear effusion: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797294" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of antimicrobial treatment of acute otitis media on the daily disappearance of middle ear effusion: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9232040" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of Auralgan for treating ear pain in children with acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156478" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Topical lignocaine for pain relief in acute otitis media: results of a double-blind placebo-controlled randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156478" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Topical lignocaine for pain relief in acute otitis media: results of a double-blind placebo-controlled randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37594020" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856108" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Topical analgesia for acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4161606" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Myringotomy in acute otitis media. A controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23340550" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reducing the frequency of acute otitis media by individualized care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28357845" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Shortened Antimicrobial Treatment for Acute Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764614" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Predictors of ear barotrauma in aircrews exposed to simulated high altitude.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828132" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Otalgia in infants traveling in airplanes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10510656" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Why does air travel cause earache?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498108" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Medical advice for commercial air travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759532" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Barotitis in children after aviation; prevalence and treatment with Otovent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323625" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pseudoephedrine and air travel-associated ear pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18646076" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Decongestants and antihistamines for acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517524" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized, placebo-controlled trial of the effect of antihistamine or corticosteroid treatment in acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285300" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The common cold and decongestant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285300" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The common cold and decongestant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120703" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081729" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23126594" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Management of Acute Otitis Media: update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930204" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968847" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159657" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536957" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Longer term outcomes from a randomised trial of prescribing strategies in otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760531" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Delayed versus immediate antimicrobial treatment for acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881007" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Delayed antibiotic prescriptions for respiratory infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999574" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute otitis media in children younger than 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226577" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A placebo-controlled trial of antimicrobial treatment for acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226576" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of acute otitis media in children under 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2011422" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332211" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: a meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432166" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432166" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432166" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24338106" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980558" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176564" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323630" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656505" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22173142" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002709" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824827" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Short-course antibiotics for acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9951971" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28666536" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30640191" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28784702" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260224" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31561959" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adverse Events of Antibiotics Used to Treat Acute Otitis Media in Children: A Systematic Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32586531" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Considering an otitis media antibiotic change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35944719" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Amoxicillin Versus Other Antibiotic Agents for the Treatment of Acute Otitis Media in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29570583" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis: Conundrum No More.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9239776" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400744" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400744" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428910" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28978716" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428889" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Antimicrobial resistance in Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31839585" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : β-Lactamase-non-producing ampicillin-resistant Haemophilus influenzae is acquiring multidrug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12839703" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : How can we predict bacterial eradication?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608648" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Review of consensus reports on management of acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443117" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18847402" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antimicrobial-resistant Streptococcus pneumoniae: trends and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18847402" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Antimicrobial-resistant Streptococcus pneumoniae: trends and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154538" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10530579" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28357844" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Shortened Antimicrobial Treatment for Acute Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002710" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Acute Otitis Media - The Long and the Short of It.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133154" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35138954" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical Practice Guideline: Tympanostomy Tubes in Children (Update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33979487" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3277153" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Five vs. ten days of therapy for acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190709" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12806297" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Topical ofloxacin for chronic suppurative otitis media and acute exacerbation of chronic otitis media: optimum duration of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848130" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Are topical antibiotics an alternative to oral antibiotics for children with acute otitis media and ear discharge?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34166300" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prevalence and Antimicrobial Resistance of Bacteria in Children With Acute Otitis Media and Ear Discharge: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12949278" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of otitis media with observation and a safety-net antibiotic prescription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450878" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comparison of two approaches to observation therapy for acute otitis media in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27599067" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Close Follow-up in Children With Acute Otitis Media Initially Managed Without Antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074019" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074019" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940232" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28146590" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Epidemiology of Otitis Media with Spontaneous Perforation of the Tympanic Membrane in Young Children and Association with Bacterial Nasopharyngeal Carriage, Recurrences and Pneumococcal Vaccination in Catalonia, Spain - The Prospective HERMES Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27729132" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : What are the leading causative pathogens in acute otitis media with tympanic membrane perforation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110050" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172354" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074838" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Methicillin-resistant Staphylococcus aureus: pediatric otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099083" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328116" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174454" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30895211" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226572" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Videos in clinical medicine. Tympanocentesis in children with acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821471" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical course, complications and sequelae of acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466224" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
